# CLINICAL UPDATE

| | |
|---|---|
| **Brand Name** | N/A |
| **Generic Name** | moxifloxacin hydrochloride |
| **Drug Manufacturer** | Mylan Labs |

## Clinical Update

### TYPE OF CLINICAL UPDATE

New Dosage Form (ophthalmic syringe)

### FDA APPROVAL DATE

N/A

### LAUNCH DATE

November 17, 2020

### REVIEW DESIGNATION

N/A

### TYPE OF REVIEW

N/A

### DISPENSING RESTRICTIONS

Open

## Overview

### INDICATION(S) FOR USE

Moxifloxacin Injection is a fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species*, Micrococcus luteus*, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus warneri*, Streptococcus pneumoniae, Streptococcus viridans group, Acinetobacter lwoffii*, Haemophilus influenzae, Haemophilus parainfluenzae*, Chlamydia trachomatis.

*Efficacy for this organism was studied in fewer than 10 infections.

### MECHANISMS OF ACTION

Moxifloxacin is a member of the fluoroquinolone class of antibacterial agents.

### DOSAGE FORM(S) AND STRENGTH(S)

Intraocular syringe/injection: 1.6mg/mL

### DOSE & ADMINISTRATION

The dose of Moxifloxacin Injection is 400 mg intravenously once every 24 hours.

This document is designed to be an informational resource to facilitate discussion and should be used neither as a basis for clinical decision-making or treatment nor as a substitute for reading original literature. RxAdvance makes every effort to ensure that the information provided is up-to-date, accurate, and complete, but no guarantee is made to that effect. If this information is provided to clients or vendors, it is subject to any contractual confidentiality provisions. Third-party disclosures are in violation of confidentiality provisions.

© RxAdvance Corporation. Confidential and Proprietary.

# CLINICAL UPDATE

## EFFICACY

The safety and efficacy of Moxifloxacin Injection in pediatric patients for the treatment of cIAI has not been demonstrated.

In controlled multiple-dose clinical trials, 23% of patients receiving oral moxifloxacin were greater than or equal to 65 years of age and 9% were greater than or equal to 75 years of age. The clinical trial data demonstrate that there is no difference in the safety and efficacy of oral moxifloxacin in patients aged 65 or older compared to younger adults.

This document is designed to be an informational resource to facilitate discussion and should be used neither as a basis for clinical decision-making or treatment nor as a substitute for reading original literature. RxAdvance makes every effort to ensure that the information provided is up-to-date, accurate, and complete, but no guarantee is made to that effect. If this information is provided to clients or vendors, it is subject to any contractual confidentiality provisions. Third-party disclosures are in violation of confidentiality provisions.

© RxAdvance Corporation. Confidential and Proprietary.